MRKR

Marker Therapeutics (MRKR)

Marker Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MRKR

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/16	05:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MRKR	Marker Therapeutics Inc
2024/04/08	20:00	GlobeNewswire Inc.	Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	NASDAQ:MRKR	Marker Therapeutics Inc
2024/03/26	06:45	GlobeNewswire Inc.	Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	NASDAQ:MRKR	Marker Therapeutics Inc
2024/03/23	01:30	GlobeNewswire Inc.	Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	NASDAQ:MRKR	Marker Therapeutics Inc
2024/03/01	22:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2024/02/26	21:58	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2024/01/22	21:30	GlobeNewswire Inc.	Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	NASDAQ:MRKR	Marker Therapeutics Inc
2024/01/08	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2024/01/08	22:24	GlobeNewswire Inc.	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	NASDAQ:MRKR	Marker Therapeutics Inc
2023/12/22	01:00	GlobeNewswire Inc.	Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	NASDAQ:MRKR	Marker Therapeutics Inc
2023/12/11	21:35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/12/11	21:00	GlobeNewswire Inc.	Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	NASDAQ:MRKR	Marker Therapeutics Inc
2023/11/21	06:37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/11/10	07:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/11/10	07:00	GlobeNewswire Inc.	Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	NASDAQ:MRKR	Marker Therapeutics Inc
2023/11/10	06:31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MRKR	Marker Therapeutics Inc
2023/09/11	20:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/09/11	20:00	GlobeNewswire Inc.	Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse	NASDAQ:MRKR	Marker Therapeutics Inc
2023/08/30	21:00	GlobeNewswire Inc.	Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:MRKR	Marker Therapeutics Inc
2023/08/15	05:37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/08/15	05:30	GlobeNewswire Inc.	Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	NASDAQ:MRKR	Marker Therapeutics Inc
2023/08/15	05:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MRKR	Marker Therapeutics Inc
2023/08/07	20:22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/08/07	20:00	GlobeNewswire Inc.	Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program	NASDAQ:MRKR	Marker Therapeutics Inc
2023/07/26	20:00	GlobeNewswire Inc.	Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023	NASDAQ:MRKR	Marker Therapeutics Inc
2023/07/10	20:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/07/10	20:00	GlobeNewswire Inc.	European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients	NASDAQ:MRKR	Marker Therapeutics Inc
2023/07/06	05:22	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MRKR	Marker Therapeutics Inc
2023/07/04	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc
2023/07/01	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MRKR	Marker Therapeutics Inc